Petroleo Brasileiro SA Petrobras
PBR
Strategy
MSTR
Vale SA
VALE
KB Home
KBH
Apple
AAPL
US Stock MarketDetailed Quotes
EVOK Evoke Pharma
- 5.3700
- -0.0300-0.56%
Close Feb 14 16:00 ET
7.98MMarket Cap-0.53P/E (TTM)
5.3700High4.9200Low6.50KVolume5.1300Open5.4000Pre Close32.85KTurnover0.51%Turnover RatioLossP/E (Static)1.49MShares12.319952wk High1.82P/B6.82MFloat Cap3.540052wk Low--Dividend TTM1.27MShs Float2052.0000Historical High--Div YieldTTM8.33%Amplitude3.5400Historical Low5.0560Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Evoke Pharma Stock Forum
anyone got any news?
📊⚡️📊
Benzinga· 2 mins ago
FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025
Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to...
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends
Thursday, 19th December at 8:30 am
FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025
Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to oral metoclopramide
SOLANA BEACH, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Phar...
Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®
Tuesday, 3rd December at 8:30 am
SOLANA BEACH, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it has received notices of allowance for two U.S. patent appli...
Evoke Pharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Laurence W. Lytton(9.99%)
will it ever rise?
No comment yet